C&L: MDS speeds transition plan

MDS has sped up its transition plan, with Stephen DeFalco stepping in sooner than expected to take over the top executive spot from John Rogers. DeFalco has been acting COO for two weeks.

Pharming has made two appointments: John Pieters was named COO and Sabine Hoekstra was hired as legal counsel.

NeoRx has appointed David A. Karlin, MD, as senior vice president of clinical development and regulatory affairs. Prior to joining NeoRx, Dr. Karlin served as vice president of clinical research at Cellegy Pharmaceuticals.

Wyeth announced the election of Ulf Wiinberg to the position of senior vice president. Wiinberg was previously president, Wyeth Consumer Healthcare.

SFBC International has appointed Joyce Lea Frey-Vasconcells, PhD, as executive director, PharmaNet, consulting division. Prior to joining PharmaNet, she was the director, Office of Cellular, Tissue, and Gene Therapies with the Center for Biologics Evaluation and Research.

Peter Leddy, PhD, is joining Invitrogen as senior vice president of human resources. Dr. Leddy most recently served as vice president of human resources for the Americas Operations of Dell.

Neurocrine Biosciences has hired Richard Ranieri to the position of senior vice president-human resources. Ranieri most recently held similar management positions at Genencor International.

HistoRx has appointed Paul Stroobant, PhD, vice president and head of research. Dr. Stroobant most recently served as vice president, Biochemistry and Protein Discovery at BG Medicine.

Nabi Biopharmaceuticals has hired Constance C. Bienfait as vice president of investor relations. Most recently, she served as executive director of corporate communications for Kos Pharmaceuticals.

Oxxon Therapeutics has appointed Craig R. Smith, MD, co-founder and former president and CEO of Guilford Pharmaceuticals, to the company's board of directors.

IsoTis OrthoBiologics has named James Hart to its board of directors.

Jean-Paul Valles, PhD, has resigned from Pfizer's board of directors.

Celsion is expanding its board and filling the resulting vacancy by electing Gregory Weaver to the board.

NeoGenomics has added three new board members: Dr. Thomas D. Conrad, George O'Leary and Peter M. Peterson.

Phase Forward has named Eve E. Slater, MD, to its board of directors.

Pharmos has named Abraham Sartani, MD, to a newly created seat on the company's board of directors.

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.